Erb-B2 receptor tyrosine kinase 2 (ERBB2) mRNA 3' untranslated region (ERBB2 3' UTR)

The Erb-B2 receptor tyrosine kinase 2 (ERBB2) mRNA 3' untranslated region (3' UTR) is a critical regulatory segment of the transcript that encodes the HER2 protein, a member of the epidermal growth factor receptor family (Source: PubMed, PMID: 21670213). This region contains multiple cis-acting elements, including microRNA response elements (MREs) and AU-rich elements, which dictate the stability and translation efficiency of the mRNA (Source: FEBS Letters, 2007). In various cancers, particularly breast and gastric carcinomas, the dysregulation of these regulatory motifs leads to the overexpression of HER2, which promotes aggressive tumor growth and poor clinical outcomes (Source: Cancer Research, 2014). As a therapeutic target, the 3' UTR is exploited by RNA-based modalities such as antisense oligonucleotides (ASOs) and siRNAs that aim to reduce HER2 levels by inducing mRNA degradation or blocking translation (Source: Molecular Therapy, 2018). These approaches provide a potential strategy to overcome resistance to traditional protein-targeted therapies like trastuzumab by depleting the mRNA pool itself (Source: Nature Reviews Drug Discovery, 2020). Furthermore, the 3' UTR is a site for endogenous regulation by microRNAs like miR-125b, which are being investigated as therapeutic mimics to restore normal growth control (Source: Nature Communications, 2014).

Other names

HER2 3' UTRHuman epidermal growth factor receptor 2 mRNA 3' untranslated regionNEU 3' UTRCD340 3' UTRERBB2 3-prime untranslated region

Therapeutic agents targeting the ERBB2 3' UTR primarily act through RNase H-mediated degradation of the mRNA transcript, RNA interference (RNAi) via the RISC complex, or by sterically hindering the binding of stabilizing proteins and microRNAs to modulate translation.